Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
32.00
+0.66 (2.11%)
Jan 14, 2026, 4:00 PM EST - Market closed
Oruka Therapeutics Employees
Oruka Therapeutics had 28 employees as of December 31, 2024.
Employees
28
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,984,659
Market Cap
1.55B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ORKA News
- 2 days ago - Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 - GlobeNewsWire
- 8 days ago - Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 9 days ago - Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears - Seeking Alpha
- 4 weeks ago - Oruka Therapeutics Announces New Board Member and Board Transition - GlobeNewsWire
- 2 months ago - Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Oruka Therapeutics to Present at Multiple November Investor Conferences - GlobeNewsWire
- 4 months ago - Oruka Therapeutics Announces $180 Million Private Placement - GlobeNewsWire
- 4 months ago - Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 - GlobeNewsWire